Drug Profile


Alternative Names: Aerosolized KL4 surfactant; Aerosurf; ATI-01; ATI-02; DSC-104; DSC-105; KL-4 lung surfactant; KL4 pulmonary surfactant; KL4 surfactant; Lucinactant; Surfaxin; Surfaxin LS

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator The Scripps Research Institute
  • Developer Discovery Laboratories; University of Pennsylvania; Windtree Therapeutics
  • Class Amino acids; Peptides; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Neonatal respiratory distress syndrome; Acute lung injury; Adult respiratory distress syndrome; Meconium aspiration syndrome; Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neonatal respiratory distress syndrome
  • Preclinical Acute lung injury; Chronic obstructive pulmonary disease; Lung disorders; Reperfusion injury
  • No development reported Adult respiratory distress syndrome; Bronchopulmonary dysplasia; Cystic fibrosis
  • Discontinued Asthma; Meconium aspiration syndrome; Otitis media; Respiratory insufficiency; Rhinitis; Sinusitis

Most Recent Events

  • 12 Jun 2017 Windtree grants Lee's Pharmaceutical Holdings exclusive license to manufacture KL4 surfactant in China for use in non-aerosol surfactant products
  • 12 Jun 2017 Windtree therapeutics and Lee's Pharmaceutical Holdings Ltd agree to co-promote and co-develop KL4 surfactant products in select Asian markets
  • 01 Jun 2017 Windtree Therapeutics completes enrolment in the phase IIb trial for Neonatal respiratory distress syndrome in North America, Europe and Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top